Inhaled PYY(3–36) dry-powder formulation for appetite suppression

References

• Pedersen-Bjergaard U, Host U, Kelbaek H, et al. Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in man. Scand J Clin Lab Invest 1996;56:497–503
   PubMed Web of Science ®Google Scholar
• Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985;89:1070–7
   PubMed Web of Science ®Google Scholar
• Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3–36) physiologically inhibits food intake. Nature 2002;418:650–4
   PubMed Web of Science ®Google Scholar
• Challis BG, Pinnock SB, Coll AP, et al. Acute effects of PYY(3–36) on food intake and hypothalamic neuropeptide expression in the mouse. Biochem. Biophys Res Commun 2003;311:915–19
   PubMed Web of Science ®Google Scholar
• Halatchev IG, Ellacott KLJ, Fan W, Cone RD. Peptide YY3–36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 2004;145:2585–90
   PubMed Web of Science ®Google Scholar
• Pittner RA, Moore CX, Bhaversusar SP, et al. Effects of PYY[3–36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 2004;28:963–71
   PubMed Web of Science ®Google Scholar
• Chelikani PK, Haver AC, Reeve JR Jr, et al. Daily intermittent intravenous infusion of peptide YY(3–36) reduces daily food intake and adiposity in rats. Am J Physiol Regul Integr Comp Physiol 2006;290:R295–305
   Google Scholar
• Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of peptide YYU(3–36) potently inhibits food intake in rats. Endocrinology 2005;146:879–88
   PubMed Web of Science ®Google Scholar
• Degen L, Oesch S, Casanova M, et al. Effect of peptide YY3–36 on food intake in humans. Gastroenterology 2005;129:1430–6
   PubMed Web of Science ®Google Scholar
• Unniappan S, McIntosh CHS, Demuth H-U, et al. Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY. Diabetologia 2006;49:1915–23
   PubMed Web of Science ®Google Scholar
• Sloth B, Davidsen L, Holst JJ, et al. Effect of subcutaneous injections of PYY1–36 and PYY3–36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Am J Physiol Endocrinol Metab 2007;293:E604–9
   PubMed Web of Science ®Google Scholar
• Weers JG, Bell J, Chan HK, et al. Pulmonary formulations: what remains to be done? J Aerosol Med Pulm Drug 2010;23:S5–23
   PubMed Web of Science ®Google Scholar
• Nadkarni PP, Costanzo RM, Sakagami M. Pulmonary delivery of peptide YY for food intake suppression and reduced body weight gain in rats. Diabetes Obes Metabol 2011;13:408–17
   PubMed Web of Science ®Google Scholar
• Bide RW, Armour SJ, Yee E. Allometric respiration/body mass data for animals to be used for estimates of inhalation toxicity to young adult humans. J Appl Toxicol 2000;20:273–90
   PubMed Web of Science ®Google Scholar
• Kuehl PJ, Anderson TL, Candelaria G, et al. Regional particle size dependent deposition of inhaled aerosols in rats and mice. Inhal Tox 2012;24:27–35
   PubMed Web of Science ®Google Scholar
• Le Roux CW, Batterham RL, Aylwin SJ, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006;147:3–8
   PubMed Web of Science ®Google Scholar
• Irikura T, Tamada T, Okada K, et al. Studies on hydroxyethyl starch solution (Hespander®) as a plasma substitute (VI). Acute toxicity tests in mice, rats and rabbits. Oyo Yakuri 1972;6:1023–30
   Google Scholar
• Arturson G, Wallenius G. The intravascular persistence of dextran of different molecular sizes in normal humans. Scand J Clin Lab Invest 1964;16:76–80
   PubMed Web of Science ®Google Scholar
• Barrowcliffe MP, Zanelli GD, Ellison D, Jones JG. Clearance of charged and uncharged dextrans from normal and injured lung. J Appl Physiol 1990;68:341–7
   PubMed Web of Science ®Google Scholar
• King M, Speert DP. Use of dextran and other polysaccharides to improve mucus clearance. U.S. Patent Application No. 20020032172; 2002
   Google Scholar
• Dubick MA, Wade CE. A review of the efficacy and safety of 7.5% NaCl/6% Dextran 70 in experimental animals and humans. J Trauma 1994;136:323–30
   Google Scholar
• BCY Lifesciences Inc., BCY LifeSciences reports successful Phase I clinical trial. News release transmitted by Data Monitor. Available from: http://www.datamonitor.com/store/News/bcy_reports_trial_results_indicating_that_inhaled_dextran_can_be_safely_utilized_to_treat_cystic_fibrosis?productid=71905E03-87B3-4814-B20E-17FC5EF5AE4E [last accessed 25 Oct 2013]
   Google Scholar
• Vodak D, Dobry DE, Friesen D, et al. Dextran-based materials as excipients in engineered particle formulations: tailoring physical properties to optimize performance, manufacturability, and safety. RDD Europe 2011;1:125–34
   Google Scholar
• Vodak DT, Channell M, McCombie D, et al. Comparative repeat exposure inhalation toxicity of dextran polymers. Poster presentation at the 49th Annual Meeting of the Society of Toxicology, Salt Lake City, UT; 2010 Mar 7–11
   Google Scholar
• Kuehl PJ, Barrett EG, McDonald JD, et al. Formulation development and in vivo evaluation of a new dry powder formulation of albuterol sulphate in beagle dogs. Pharm Res 2010;27:894–904
   PubMed Web of Science ®Google Scholar
• Kuehl PJ, Cherrington A, Dobry DE, et al. Biological comparison of inhaled insulin formulations: exubera and novel spray-dried engineered particles of dextran-10. AAPS PharmSciTech 2014;15:1545–50
   PubMed Web of Science ®Google Scholar
• Shamblin SL, Taylor LS, Zografi G. Mixing behavior of colyophilized binary systems. J Pharm Sci 1998;87:694–701
   PubMed Web of Science ®Google Scholar